There were nine startup fundings disclosed at midweek in the Bay Area, totaling nearly $340 million. Here are the details. • Collective Health Inc., San Francisco, $110 million: New investors in this developer of a workforce health management system include Sun Life Financial and Mubadala Ventures. They were joined in this round by return backers New Enterprise Associates, Founders Fund, GV (formerly Google Ventures) and Maverick Ventures • Aurora Innovation Inc., Palo Alto, $90 million: This…
Reported by bizjournals 5 hours ago.
The Funded: 9 Bay Area startups raise nearly $340M at midweek
↧
↧
Global Medical Marijuana Offering Business Opportunity in Medical Industry and is projected to Reach USD 28.07 billion, by 2024: Energias Market Research Pvt. Ltd.
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- The global medical marijuana market is expected to grow significantly from *USD 8.28 billion in 2017* to *USD 28.07 billion in 2024*, at a *CAGR of 19.1% from 2018 to 2024.* Factors propelling the growth of medical marijuana market are *growing awareness regarding the benefits of its various applications,* increasing demand for marijuana in the treatment of various diseases, and growing *number of research and development activities .* However, legality issues in various nations is the key restraints to the growth of the market.
The report segment the global medical marijuana market by *Types *(sativa, indica, and hybrid), by *Medical Application *(glaucoma, inflammatory bowel diseases, chronic pain, migraine, arthritis, anxiety, insomnia, AIDS, and others), by* Chemical Derivatives* (THC(delta-9-tetrahydrocannabinol), CBD (cannabidiol) CBD capsules, CBD tincture or liquids, and CBD topical), and hybrid (combination of THC & CBD), by *End-User* (pharmaceutical industry, hospital, research and development centers, and pharmacy stores) and by *Region *(North America, South America, Europe, Middle East and Africa, and Asia-Pacific).
Medical marijuana is uses as the whole plant or plant extract for the treatment of various diseases. THC (delta-9-tetrahydrocannabinol) is the main active mind-altering (psychoactive) substance found in marijuana plant having medical properties to treat vomiting, nausea, and other medical conditions. THC (delta-9-tetrahydrocannabinol) is also used to treat appetite in patients suffering from AIDS.
*Browse full research report with TOC on “Global Medical Marijuana Market, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation and Forecast 2024” at: https://www.energiasmarketresearch.com/global-medical-marijuana-market-outlook/ *
*To purchase report: **sales@energiasmarketresearch.com*
*Key Findings of the Global Medical Marijuana Market Report*
· The global medical marijuana market is expected to reach USD 28.07 billion by 2024 at CAGR of 19.1% form 2018-2024
· Based on the Medical Application, the chronic pain segment held the major share of the global market in 2017, due to hundreds of chemical compounds found in marijuana which help in treat pain management
· Based on the Chemical Derivatives, the CBD (cannabidiol) holds the major share of the global medical marijuana market, owing to increasing research and development activities along with the growing demand in application such as capsules, tincture, gum, vape oil, and bath products
· On the basis of End-User, the Pharmaceutical Industry holds the major share of the global medical marijuana market. The increasing demand by pharmaceutical industry is owed to usage of medical marijuana to develop new drugs for medical treatments of patients
· Geographically, North America holds the largest share in the global medical marijuana market and is expected to register high growth rate over the forecast period. The growth in the region is attributed to growing number of U.S states legalizing the use of marijuana in the medical applications
· The key players operating in the medical marijuana market are American Cannabis Company, Inc. Cannabis Sativa, Inc, GrowBlox Sciences, Inc, GW Pharmaceuticals, United Cannabis Corporation, Corbus Pharmaceuticals, Insys Therapeutics, Inc. and Lexaria Corporation, Canopy Growth Corporation, Growblox Sciences, Inc Aurora Cannabis, AXIM Biotechnologies Inc, MEDICAL MARIJUANA, INC. Arena Pharmaceuticals, and Cara Therapeutics
*Global Medical Marijuana- offering business opportunity in medical industry *
Medical marijuana plant contains many chemical properties that may help in treating a wide range of diseases and symptoms. The medical marijuana plant having two major strains: cannabis sativa and cannabis indica. The cannabis sativas have a higher level of TCH (delta-9 tetrahydrocannabinol) resulting in a medical application such as control of nausea, vomiting, and stimulate appetite in AIDS patients. The cannabis indica have a higher level of CBD (cannabidiol), resulting in treatment of symptoms such as muscle spasms, chronic pain, anxiety and sleep deprivation. The industry size for medical marijuana is increasing primarily in U.S. offering business opportunity with high profit margins. However, federal prohibition remains to be key restraint to market growth across the globe.
*Global Medical Marijuana Market – Regional Insight*
Geographically, the global medical marijuana market is segmented into North America, South America, Europe, Middle East and Africa, and Asia-Pacific. North America holds the largest share in the global medical marijuana market and is expected to show high growth rate owing to growing number of U.S states, legalizing the use of marijuana in the medical applications. Europe holds the second largest share in the global medical marijuana market in 2017. Growing importance of cannabis sector with initiative to legalize coupled with rising awareness among people for its medical usage augments the growth of medical marijuana market in Europe. However, the North America region is expected to witness the fastest growth during the period 2018–2024. This high growth is attributed to increasing awareness about the medical marijuana and government legalization for its medical use.*About Energias Market Research Pvt. Ltd.** -*
Energias Market Research Pvt. Ltd. publishes high-quality reports, in-depth market research studies, to help clients obtain investment level clarity on the current business scenario, trends, and segmentation for their future developments. We are committed to our client’s needs, by providing high-quality custom reports solutions best fit for strategy development and implementation to a high return of invest (RoI). We believe that exceptional problems need the expertise to solve, and with the help of our industries expertise, we are able to offer an in-depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that include *energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc.* We strive to provide our clients with a one-stop solution for all research and consulting needs.
*Contact: *
*Mr. Manas Nagi
*Business Development Manager
*For any queries email us: **info@energiasmarketresearch.com
**To purchase report: **sales@energiasmarketresearch.com
**Call us: +1-716-239-4915
**Visit: **https://www.energiasmarketresearch.com/* Reported by GlobeNewswire 4 hours ago.
The report segment the global medical marijuana market by *Types *(sativa, indica, and hybrid), by *Medical Application *(glaucoma, inflammatory bowel diseases, chronic pain, migraine, arthritis, anxiety, insomnia, AIDS, and others), by* Chemical Derivatives* (THC(delta-9-tetrahydrocannabinol), CBD (cannabidiol) CBD capsules, CBD tincture or liquids, and CBD topical), and hybrid (combination of THC & CBD), by *End-User* (pharmaceutical industry, hospital, research and development centers, and pharmacy stores) and by *Region *(North America, South America, Europe, Middle East and Africa, and Asia-Pacific).
Medical marijuana is uses as the whole plant or plant extract for the treatment of various diseases. THC (delta-9-tetrahydrocannabinol) is the main active mind-altering (psychoactive) substance found in marijuana plant having medical properties to treat vomiting, nausea, and other medical conditions. THC (delta-9-tetrahydrocannabinol) is also used to treat appetite in patients suffering from AIDS.
*Browse full research report with TOC on “Global Medical Marijuana Market, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation and Forecast 2024” at: https://www.energiasmarketresearch.com/global-medical-marijuana-market-outlook/ *
*To purchase report: **sales@energiasmarketresearch.com*
*Key Findings of the Global Medical Marijuana Market Report*
· The global medical marijuana market is expected to reach USD 28.07 billion by 2024 at CAGR of 19.1% form 2018-2024
· Based on the Medical Application, the chronic pain segment held the major share of the global market in 2017, due to hundreds of chemical compounds found in marijuana which help in treat pain management
· Based on the Chemical Derivatives, the CBD (cannabidiol) holds the major share of the global medical marijuana market, owing to increasing research and development activities along with the growing demand in application such as capsules, tincture, gum, vape oil, and bath products
· On the basis of End-User, the Pharmaceutical Industry holds the major share of the global medical marijuana market. The increasing demand by pharmaceutical industry is owed to usage of medical marijuana to develop new drugs for medical treatments of patients
· Geographically, North America holds the largest share in the global medical marijuana market and is expected to register high growth rate over the forecast period. The growth in the region is attributed to growing number of U.S states legalizing the use of marijuana in the medical applications
· The key players operating in the medical marijuana market are American Cannabis Company, Inc. Cannabis Sativa, Inc, GrowBlox Sciences, Inc, GW Pharmaceuticals, United Cannabis Corporation, Corbus Pharmaceuticals, Insys Therapeutics, Inc. and Lexaria Corporation, Canopy Growth Corporation, Growblox Sciences, Inc Aurora Cannabis, AXIM Biotechnologies Inc, MEDICAL MARIJUANA, INC. Arena Pharmaceuticals, and Cara Therapeutics
*Global Medical Marijuana- offering business opportunity in medical industry *
Medical marijuana plant contains many chemical properties that may help in treating a wide range of diseases and symptoms. The medical marijuana plant having two major strains: cannabis sativa and cannabis indica. The cannabis sativas have a higher level of TCH (delta-9 tetrahydrocannabinol) resulting in a medical application such as control of nausea, vomiting, and stimulate appetite in AIDS patients. The cannabis indica have a higher level of CBD (cannabidiol), resulting in treatment of symptoms such as muscle spasms, chronic pain, anxiety and sleep deprivation. The industry size for medical marijuana is increasing primarily in U.S. offering business opportunity with high profit margins. However, federal prohibition remains to be key restraint to market growth across the globe.
*Global Medical Marijuana Market – Regional Insight*
Geographically, the global medical marijuana market is segmented into North America, South America, Europe, Middle East and Africa, and Asia-Pacific. North America holds the largest share in the global medical marijuana market and is expected to show high growth rate owing to growing number of U.S states, legalizing the use of marijuana in the medical applications. Europe holds the second largest share in the global medical marijuana market in 2017. Growing importance of cannabis sector with initiative to legalize coupled with rising awareness among people for its medical usage augments the growth of medical marijuana market in Europe. However, the North America region is expected to witness the fastest growth during the period 2018–2024. This high growth is attributed to increasing awareness about the medical marijuana and government legalization for its medical use.*About Energias Market Research Pvt. Ltd.** -*
Energias Market Research Pvt. Ltd. publishes high-quality reports, in-depth market research studies, to help clients obtain investment level clarity on the current business scenario, trends, and segmentation for their future developments. We are committed to our client’s needs, by providing high-quality custom reports solutions best fit for strategy development and implementation to a high return of invest (RoI). We believe that exceptional problems need the expertise to solve, and with the help of our industries expertise, we are able to offer an in-depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that include *energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc.* We strive to provide our clients with a one-stop solution for all research and consulting needs.
*Contact: *
*Mr. Manas Nagi
*Business Development Manager
*For any queries email us: **info@energiasmarketresearch.com
**To purchase report: **sales@energiasmarketresearch.com
**Call us: +1-716-239-4915
**Visit: **https://www.energiasmarketresearch.com/* Reported by GlobeNewswire 4 hours ago.
↧
SculptMed Expands Wellness and Aesthetic Services
SculptMed, a physician-owned and -operated medspa in the Denver area providing leading minimally- and non-invasive aesthetic and wellness treatments, has expanded its location to accommodate its growing selection of cosmetic and wellness services, including cryotherapy, IV Hydration, NormaTec® Pulsed Compression Therapy, DermalInfusion® Skin Resurfacing, and microblading.
DENVER (PRWEB) March 01, 2018
SculptMed is excited to announce its expansion to provide leading wellness services, including cryotherapy, IV Hydration, and NormaTec Pulsed Compression Therapy. SculptMed’s expanded facility provides a safe, comfortable, and serene environment for its leading selection of treatments.
SculptMed utilizes one of the safest cryosaunas on the market from Impact Cryotherapy to provide Whole Body Cryotherapy, which exposes the body to a brief period of freezing air to promote wellness and healing. SculptMed’s IV Hydration station offers an extensive menu of IV cocktails for replenishing hydration and essential nutrients, such as the Weekend Warrior Cocktail to speed athletic recovery and the Apple Cocktail with immunity-boosting nutrients for staving off the cold, flu, and other common illnesses. Last, but not least, NormaTec Pulsed Compression Therapy is a patented compression device used by many professional athletes to speed healing and soothe muscles after intense workouts or athletic competitions.
SculptMed also recently expanded its aesthetic services to include DermalInfusion Skin Resurfacing, microblading, and ModMicroMakeup, a specialized form of permanent makeup by renowned makeup artist Kari Kisch.
Located at The Streets at Southglenn Mall, in Centennial, SculptMed is a medical spa dedicated to helping patients in the Denver area reach their aesthetic and wellness goals. SculptMed’s variety of treatments help patients address a number of aesthetic concerns, including excess fat, fine lines and wrinkles, unwanted hair, hair loss, and cellulite. SculptMed’s menu of aesthetic treatments includes Botox® and dermal fillers, SculpSure® non-invasive fat reduction, platelet-rich plasma (PRP) skin rejuvenation therapy, skin tightening, DermalInfusion skin resurfacing facial treatment, tattoo removal, photofacials, microblading, and more.
SculptMed is convenient to patients in the Centennial, Highlands Ranch, Littleton, Lakewood, and Aurora areas. To learn more about services and treatments, call SculptMed at 720.287.1260 and visit http://www.sculptmed.net.
About SculptMed in Centennial, Colorado
Doctors Julian Orenstein, Robert Kilpatrick, and David Stocker have joined forces at SculptMed, bringing years of emergency medical expertise to provide the highest quality laser, cosmetic, and wellness treatments in the Denver area.
Injectable treatments at SculptMed include Botox, Juvéderm®, and Voluma®. For fat-reduction, SculptMed offers Kybella® and SculpSure. For non-invasive laser skin rejuvenation, SculptMed provides IPL photofacials and non-ablative fractional laser skin resurfacing. SculptMed also offers non-invasive Pellevé® skin tightening and Pellefirm cellulite reduction. Additional services include DermalInfusion non-invasive skin-resurfacing facials, clinical facials, IV infusion therapy, cryotherapy, NormaTec pulsed compression therapy, and platelet-rich-plasma (PRP) skin and hair rejuvenation.
About Dr. Julian Orenstein
Dr. Julian Orenstein is board-certified in both pediatrics and pediatric medicine, and teaches as an Associate Clinical Professor of Pediatrics and Emergency Room Medicine at George Washington and Georgetown Medical Centers. As a national teaching faculty member of The American Academy of Pediatrics, Dr. Orenstein has trained physicians for over 25 years. Since 1991, he has practiced both emergency medicine and pediatrics at Inova Fairfax, Children’s National, and Shady Grove Adventist Hospitals. Dr. Orenstein has been published in a variety of publications, including peer-reviewed journals such as Pediatrics and Annals of Emergency Medicine.
About Dr. Robert Kilpatrick
Dr. Robert Kilpatrick is a graduate of the Medical College of Wisconsin, and is board-certified by the American Board of Pediatrics. He conducted his residency in pediatrics at University of Nevada in Reno, and his fellowship at the University of Iowa Hospitals and Clinics in the Pediatric Cardiology department. Dr. Kilpatrick has been published in the peer-reviewed Journal Maternal-Fetal Neonatal Medicine.
About Dr. David Stocker
A graduate of the University of Colorado, Dr. David Stocker is the Medical Director of the Pediatric Emergency Department at Sky Ridge Hospital in Lone Tree, CO. Prior to Sky Ridge, Dr. Stocker served as the Medical Director of the Pediatric Emergency Department at The Medical Center of Aurora, and then as the Sunrise Children’s Hospital’s Director of the Emergency Department. Dr. David Stocker was named one of 5280 Magazine’s Top Doctors in 2009 for Pediatric Emergency Medicine. Reported by PRWeb 17 minutes ago.
DENVER (PRWEB) March 01, 2018
SculptMed is excited to announce its expansion to provide leading wellness services, including cryotherapy, IV Hydration, and NormaTec Pulsed Compression Therapy. SculptMed’s expanded facility provides a safe, comfortable, and serene environment for its leading selection of treatments.
SculptMed utilizes one of the safest cryosaunas on the market from Impact Cryotherapy to provide Whole Body Cryotherapy, which exposes the body to a brief period of freezing air to promote wellness and healing. SculptMed’s IV Hydration station offers an extensive menu of IV cocktails for replenishing hydration and essential nutrients, such as the Weekend Warrior Cocktail to speed athletic recovery and the Apple Cocktail with immunity-boosting nutrients for staving off the cold, flu, and other common illnesses. Last, but not least, NormaTec Pulsed Compression Therapy is a patented compression device used by many professional athletes to speed healing and soothe muscles after intense workouts or athletic competitions.
SculptMed also recently expanded its aesthetic services to include DermalInfusion Skin Resurfacing, microblading, and ModMicroMakeup, a specialized form of permanent makeup by renowned makeup artist Kari Kisch.
Located at The Streets at Southglenn Mall, in Centennial, SculptMed is a medical spa dedicated to helping patients in the Denver area reach their aesthetic and wellness goals. SculptMed’s variety of treatments help patients address a number of aesthetic concerns, including excess fat, fine lines and wrinkles, unwanted hair, hair loss, and cellulite. SculptMed’s menu of aesthetic treatments includes Botox® and dermal fillers, SculpSure® non-invasive fat reduction, platelet-rich plasma (PRP) skin rejuvenation therapy, skin tightening, DermalInfusion skin resurfacing facial treatment, tattoo removal, photofacials, microblading, and more.
SculptMed is convenient to patients in the Centennial, Highlands Ranch, Littleton, Lakewood, and Aurora areas. To learn more about services and treatments, call SculptMed at 720.287.1260 and visit http://www.sculptmed.net.
About SculptMed in Centennial, Colorado
Doctors Julian Orenstein, Robert Kilpatrick, and David Stocker have joined forces at SculptMed, bringing years of emergency medical expertise to provide the highest quality laser, cosmetic, and wellness treatments in the Denver area.
Injectable treatments at SculptMed include Botox, Juvéderm®, and Voluma®. For fat-reduction, SculptMed offers Kybella® and SculpSure. For non-invasive laser skin rejuvenation, SculptMed provides IPL photofacials and non-ablative fractional laser skin resurfacing. SculptMed also offers non-invasive Pellevé® skin tightening and Pellefirm cellulite reduction. Additional services include DermalInfusion non-invasive skin-resurfacing facials, clinical facials, IV infusion therapy, cryotherapy, NormaTec pulsed compression therapy, and platelet-rich-plasma (PRP) skin and hair rejuvenation.
About Dr. Julian Orenstein
Dr. Julian Orenstein is board-certified in both pediatrics and pediatric medicine, and teaches as an Associate Clinical Professor of Pediatrics and Emergency Room Medicine at George Washington and Georgetown Medical Centers. As a national teaching faculty member of The American Academy of Pediatrics, Dr. Orenstein has trained physicians for over 25 years. Since 1991, he has practiced both emergency medicine and pediatrics at Inova Fairfax, Children’s National, and Shady Grove Adventist Hospitals. Dr. Orenstein has been published in a variety of publications, including peer-reviewed journals such as Pediatrics and Annals of Emergency Medicine.
About Dr. Robert Kilpatrick
Dr. Robert Kilpatrick is a graduate of the Medical College of Wisconsin, and is board-certified by the American Board of Pediatrics. He conducted his residency in pediatrics at University of Nevada in Reno, and his fellowship at the University of Iowa Hospitals and Clinics in the Pediatric Cardiology department. Dr. Kilpatrick has been published in the peer-reviewed Journal Maternal-Fetal Neonatal Medicine.
About Dr. David Stocker
A graduate of the University of Colorado, Dr. David Stocker is the Medical Director of the Pediatric Emergency Department at Sky Ridge Hospital in Lone Tree, CO. Prior to Sky Ridge, Dr. Stocker served as the Medical Director of the Pediatric Emergency Department at The Medical Center of Aurora, and then as the Sunrise Children’s Hospital’s Director of the Emergency Department. Dr. David Stocker was named one of 5280 Magazine’s Top Doctors in 2009 for Pediatric Emergency Medicine. Reported by PRWeb 17 minutes ago.
↧
$90M raised for autonomous-driving startup Aurora
-More-
Reported by SmartBrief 7 hours ago.
↧
Ohio revenge porn bill could protect human dignity, priest says
Cincinnati, Ohio, Mar 2, 2018 / 03:15 am (CNA/EWTN News).- An Ohio priest praised a proposed state law to criminalize the nonconsensual publishing of sexual videos or photos, known as “revenge porn.”
Monsignor John Zuraw, chancellor of the Diocese of Youngstown, Ohio, told CNA that he believes the legislation would help protect the dignity of Ohio’s residents.
“When we look at that idea of what porn is all about, porn promotes harmful and destructive views of the human person,” said Monsignor Ziraw. “Revenge porn laws protect the dignity of the human person.”
Revenge porn is when an ex-romantic partner – or a hacker – posts sexual videos or photos of a person without their consent.
More than 30 states currently have laws against revenge porn, but Ohio only prosecutes the posting of pornography featuring underage children, or pornography used as blackmail. The state currently does not penalize a person for simply distributing non-consensual pornography.
Introduced to the Ohio Senate on January 25, the bill was sponsored by Senator Joe Schiavoni, who had unsuccessfully introduced similar legislation in 2016. The bill has now gained support from members of the Aurora police force, including Chief Bryan Byard and Detective Sgt. Dan Kalk.
The bill would provide “compensatory and punitive damages for harm resulting from the violation” and a “temporary restraining order prohibiting further dissemination of the image.”
According to Record-Courier, Detective Kalk, who is also an attorney, helped craft the bill after Aurora authorities struggled to find a charge for alleged offenders of revenge porn.
He said the bill would help clarify which jurisdiction should investigate or prosecute a specific crime, which can be unclear if a perpetrator is in a different city from where the victim lives.
Additionally, he said the legislation would forbid employers and universities from discriminating against victims.
Monsignor Zuraw explained that all pornography “debases the human person,” but said that revenge porn adds an additional dimension of harm.
“When we move into…revenge porn, there are two aspects there: it is the pornography that promotes harmful and destructive views of the human person, but then that whole aspect of revenge that I’m getting back at you because you didn’t do what you should be doing for me.”
Monsignor Zuraw emphasized that human sexuality is an extension of God’s goodness, but must be seen in the context of God’s creation.
“When God created each every one of us, he created our sexuality as an aspect of what is good. We should never lose sight of what God has created and ultimately what is good is to benefit us in ways that are not selfish.”
Reported by CNA 9 hours ago.
Monsignor John Zuraw, chancellor of the Diocese of Youngstown, Ohio, told CNA that he believes the legislation would help protect the dignity of Ohio’s residents.
“When we look at that idea of what porn is all about, porn promotes harmful and destructive views of the human person,” said Monsignor Ziraw. “Revenge porn laws protect the dignity of the human person.”
Revenge porn is when an ex-romantic partner – or a hacker – posts sexual videos or photos of a person without their consent.
More than 30 states currently have laws against revenge porn, but Ohio only prosecutes the posting of pornography featuring underage children, or pornography used as blackmail. The state currently does not penalize a person for simply distributing non-consensual pornography.
Introduced to the Ohio Senate on January 25, the bill was sponsored by Senator Joe Schiavoni, who had unsuccessfully introduced similar legislation in 2016. The bill has now gained support from members of the Aurora police force, including Chief Bryan Byard and Detective Sgt. Dan Kalk.
The bill would provide “compensatory and punitive damages for harm resulting from the violation” and a “temporary restraining order prohibiting further dissemination of the image.”
According to Record-Courier, Detective Kalk, who is also an attorney, helped craft the bill after Aurora authorities struggled to find a charge for alleged offenders of revenge porn.
He said the bill would help clarify which jurisdiction should investigate or prosecute a specific crime, which can be unclear if a perpetrator is in a different city from where the victim lives.
Additionally, he said the legislation would forbid employers and universities from discriminating against victims.
Monsignor Zuraw explained that all pornography “debases the human person,” but said that revenge porn adds an additional dimension of harm.
“When we move into…revenge porn, there are two aspects there: it is the pornography that promotes harmful and destructive views of the human person, but then that whole aspect of revenge that I’m getting back at you because you didn’t do what you should be doing for me.”
Monsignor Zuraw emphasized that human sexuality is an extension of God’s goodness, but must be seen in the context of God’s creation.
“When God created each every one of us, he created our sexuality as an aspect of what is good. We should never lose sight of what God has created and ultimately what is good is to benefit us in ways that are not selfish.”
Reported by CNA 9 hours ago.
↧
↧
Hybrid Kinetic Group HK GT: elongated two-door design previewed
New concept will feature elongated passenger doors
Italian design house Pininfarina has produced this shape for a Hong Kong car company; it will be revealed at the Geneva motor show
Pininfarina has designed a coupé concept called the HK GT for Hong Kong-based Hybrid Kinetic Group (HKG) that features a unique body with elongated doors.
As shown by the third preview image to be released ahead of the Geneva motor show, the car has two doors but they span the length of two seat rows.
HKG has confirmed that the four-seater model uses its electric powertrain technology, with a micro-turbine generator acting as a range extender. No statistics have been revealed but this technology was featured in HKG’s K550 and K750 SUVs and H600 saloon, which were revealed in concept forms last year with the promise of 621-mile-range battery packs with 50,000-charge-cycle lifespans.
Given its more sporting focus, the GT is expected to trade some ultimate range for added performance.
HKG's 2017 concepts were said to produce over 800bhp from their electric motors, with the saloon claimed to take 2.9sec to get from 0-60mph. The GT could therefore beat those numbers and become a threat to Tesla’s quickest Model S, the P100D, which covers the sprint in 2.4sec.
Pininfarina’s designers have applied what the company calls Italian “classic architecture” to the exterior, while also continuing the design language first seen on HKG's 2017 concepts. Those cars featured large front grilles that extended into slim headlights, meaning the GT will almost certainly feature that.
Such a technique of ‘Russian doll design’ is common practice for new brands trying to create a clear image that makes their models instantly recognisable. All four of HKG’s concept models are due to be displayed at the Geneva motor show, where the GT will make its public debut.
HKG and Pininfarina have been working together in a technical collaboration worth £55 million. Among the Hong Kong company's existing portfolio is an electric bus and a car that can be fuelled with bio-alcohol, propane and natural gas.
*More content:*
*600bhp Pininfarina Fittipaldi EF7 track car revealed *
*Byton electric SUV to feature level 4 autonomy with Aurora tech* Reported by Autocar 6 hours ago.
Italian design house Pininfarina has produced this shape for a Hong Kong car company; it will be revealed at the Geneva motor show
Pininfarina has designed a coupé concept called the HK GT for Hong Kong-based Hybrid Kinetic Group (HKG) that features a unique body with elongated doors.
As shown by the third preview image to be released ahead of the Geneva motor show, the car has two doors but they span the length of two seat rows.
HKG has confirmed that the four-seater model uses its electric powertrain technology, with a micro-turbine generator acting as a range extender. No statistics have been revealed but this technology was featured in HKG’s K550 and K750 SUVs and H600 saloon, which were revealed in concept forms last year with the promise of 621-mile-range battery packs with 50,000-charge-cycle lifespans.
Given its more sporting focus, the GT is expected to trade some ultimate range for added performance.
HKG's 2017 concepts were said to produce over 800bhp from their electric motors, with the saloon claimed to take 2.9sec to get from 0-60mph. The GT could therefore beat those numbers and become a threat to Tesla’s quickest Model S, the P100D, which covers the sprint in 2.4sec.
Pininfarina’s designers have applied what the company calls Italian “classic architecture” to the exterior, while also continuing the design language first seen on HKG's 2017 concepts. Those cars featured large front grilles that extended into slim headlights, meaning the GT will almost certainly feature that.
Such a technique of ‘Russian doll design’ is common practice for new brands trying to create a clear image that makes their models instantly recognisable. All four of HKG’s concept models are due to be displayed at the Geneva motor show, where the GT will make its public debut.
HKG and Pininfarina have been working together in a technical collaboration worth £55 million. Among the Hong Kong company's existing portfolio is an electric bus and a car that can be fuelled with bio-alcohol, propane and natural gas.
*More content:*
*600bhp Pininfarina Fittipaldi EF7 track car revealed *
*Byton electric SUV to feature level 4 autonomy with Aurora tech* Reported by Autocar 6 hours ago.
↧
Public Access TV - Street Safari
A mixed but often inspired return from the New Yorkers...As our minds wither with the lack of vitamin D and seasonal depression, *Public Access TV’s* sophomore offers some desperately needed sunshine tinted disco chords to make it to spring.
'Street Safari' opens with greasy guitar hooks, soon to be framed by the flamboyant basslines that are go to define the release. Opener ‘Safari (In My Head)’ in many ways sums up what to expect from the record: the 70’s tinged melody and experimental flair shows off 'Street Safari’s expansive palette, and perhaps the band’s new flow.
Seizing momentum with their subtly changing soundscape and soulful lyrics, Public Access TV have grown into themselves. The New Yorkers’ new wave mantras are almost underwhelming in their effortlessness. The initial swagger and sleekness stay intact through the eleven tracks of the release.
Though the groove remains, it wears a little thin. The firm foundation of the songs can be, at times, a little monotonous, a listening experience that not even the more jazzy guitar work can save. That being said, the band still oozes of swanky confidence. An ability to revitalise nostalgia, contextualised in the climate of the current day and age is what really distinguish Public Access TV from the backdrop of New York guitar bands.
Throughout 'Street Safari', Public Access TV shows off their many musical skills, their love for throwbacks, and most of all their ability to create joyous fun out of cliché lyrical lines and glossy hooks. Closing with hazy gem ‘The Quicksand’ Public Access TV show the peak of their magic, culminating in a bass-heavy swooning misty melody, a layered marvel that sets the perfect punctuation to disco adventure.
*7/10*
Words: *Aurora Henni Krogh*
- - -
- - -
Join us on *Vero*, as we get under the skin of global cultural happenings. Follow *Clash Magazine* as we skip merrily between clubs, concerts, interviews and photo shoots. Get backstage sneak peeks and a true view into our world as the fun and games unfold.
**B*uy Clash Magazine* Reported by Clash 4 hours ago.
↧
Alectra supports local communities with $385,000 United Way donation
MISSISSAUGA, Ontario, March 02, 2018 (GLOBE NEWSWIRE) -- Alectra Utilities presented United Way with a cheque for $385,180.50 Friday in support of the communities served by the utility in Hamilton, Simcoe Country, St. Catharines, Peel and York Regions.The announcement was made at Alectra’s head office on Friday as part of an official cheque presentation involving several company officials including Norm Loberg, Alectra’s Board Chair; Brian Bentz, President and CEO, Alectra Inc.; Max Cananzi, President, Alectra Utilities; Bill Schmidt, VP Information Technology and Campaign co-chair.
The $385,000 cheque was presented to Raj Chandegra, Manager Resource Development, United Way Peel Region; Ciaran McGeown, Manager, Corporate Donor Relations, United Way Toronto & York Region; Mary Thomas, Director Strategic Development, United Way Simcoe County; Christine Lynch, Resource Development Manager, United Way Halton-Hamilton; and Mandy Cavasin, Campaign Associate, United Way St. Catharines.
The funds were raised through multiple initiatives Alectra Utilities’ employees held throughout 2017, including the company’s annual charity golf tournament and an employee driven United Way campaign which generated over $85,000 alone.
“Giving back to the communities we serve is an integral part of Alectra’s values,” says Brian Bentz, President and CEO of Alectra Inc. “As we move forward in building our company, supporting charitable organizations like the United Way will continue to be important to our management and staff, Board of Directors and Shareholders.”
Alectra is proud to help foster sustainable communities by focusing on economic efficiency, social equity and environmental accountability. The donation is in addition to the already $90,000 delivered to the Mississauga Food Bank and $15,000 for Peel Children’s Centre.
Learn more about Alectra’s community efforts at www.alectra.com.
*About Alectra *
Alectra Utilities Corporation serves approximately one million customers across a 2,200 sq. km service territory and 15 communities including Alliston, Aurora, Barrie, Beeton, Brampton, Bradford, Hamilton, Markham, Mississauga, Penetanguishene, Richmond Hill, St. Catharines, Thornton, Tottenham and Vaughan. It is part of the Alectra family of companies, which also includes Alectra Inc. and Alectra Energy Solutions Inc.
*About the United Way*
A fully registered not-for profit organization, with a federated network of over 90 offices, United Way’s mission is focused on improving lives and building communities by engaging individuals and inspiring collective action.
*Media Contact:* Rachel Bertone, Media Spokesperson
rachel.bertone@alectrautilities.com | Telephone: 647.339.3826 | 24/7 Media Line: 1.833.MEDIALN
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5d4c7292-281f-4795-b520-55da67da829c Reported by GlobeNewswire 3 hours ago.
The $385,000 cheque was presented to Raj Chandegra, Manager Resource Development, United Way Peel Region; Ciaran McGeown, Manager, Corporate Donor Relations, United Way Toronto & York Region; Mary Thomas, Director Strategic Development, United Way Simcoe County; Christine Lynch, Resource Development Manager, United Way Halton-Hamilton; and Mandy Cavasin, Campaign Associate, United Way St. Catharines.
The funds were raised through multiple initiatives Alectra Utilities’ employees held throughout 2017, including the company’s annual charity golf tournament and an employee driven United Way campaign which generated over $85,000 alone.
“Giving back to the communities we serve is an integral part of Alectra’s values,” says Brian Bentz, President and CEO of Alectra Inc. “As we move forward in building our company, supporting charitable organizations like the United Way will continue to be important to our management and staff, Board of Directors and Shareholders.”
Alectra is proud to help foster sustainable communities by focusing on economic efficiency, social equity and environmental accountability. The donation is in addition to the already $90,000 delivered to the Mississauga Food Bank and $15,000 for Peel Children’s Centre.
Learn more about Alectra’s community efforts at www.alectra.com.
*About Alectra *
Alectra Utilities Corporation serves approximately one million customers across a 2,200 sq. km service territory and 15 communities including Alliston, Aurora, Barrie, Beeton, Brampton, Bradford, Hamilton, Markham, Mississauga, Penetanguishene, Richmond Hill, St. Catharines, Thornton, Tottenham and Vaughan. It is part of the Alectra family of companies, which also includes Alectra Inc. and Alectra Energy Solutions Inc.
*About the United Way*
A fully registered not-for profit organization, with a federated network of over 90 offices, United Way’s mission is focused on improving lives and building communities by engaging individuals and inspiring collective action.
*Media Contact:* Rachel Bertone, Media Spokesperson
rachel.bertone@alectrautilities.com | Telephone: 647.339.3826 | 24/7 Media Line: 1.833.MEDIALN
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5d4c7292-281f-4795-b520-55da67da829c Reported by GlobeNewswire 3 hours ago.
↧
Aurora transportation firm Schneider National Carriers cuts 119 jobs
Schneider National Carriers is cutting 119 jobs at its Aurora facility after losing a business services contract with General Motors and Ford, according to a letter filed with the state's Department of Labor.
Reported by Denver Post 1 week ago.
↧
↧
From Genes and Cells to Saving Lives: NEJM Reports Positive Results for Larotrectinib against TRK-fusion Cancers
Basic science from University of Colorado Cancer Center leads to clinical trial results reported in New England Journal of Medicine: Of 55 patients with TRK-fusion cancer who progressed after standard-of-care treatment, 44 responded to larotrectinib, with 38 remaining on the trial or receiving surgery with curative intent at median 9.4 month follow-up.
AURORA, Colo. (PRWEB) February 22, 2018
In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD, and Dana-Farber Cancer Institute investigator Pasi A. Jänne, MD, PhD reported in Nature Medicine the presence of TRK gene fusions as oncogenic drivers in patient samples of non-small cell lung cancer. Now five years later, the New England Journal of Medicine has published results of three early studies of the drug larotrectinib (formerly LOXO-101) to treat advanced-stage cancer patients whose tumors harbor these TRK fusion genes.
“The story of this drug demonstrates a new paradigm in anti-cancer drug development. We have discovery and validation of a new oncogenic driver, creation of an assay to find which cancers harbor TRK fusions, drug design and preclinical testing, and now academia-industry partnership that produces very promising clinical results,” says Doebele, director of the CU Cancer Center Thoracic Oncology Research Initiative and co-author of the current study.
The three clinical trials looked for TRK fusion genes in patients whose cancers had progressed after standard-of-care treatment (a phase 1 study involving adults, a phase 1–2 study involving children, and a phase 2 study involving adolescents and adults). Overall, 55 patients ranging in age from 4 months to 76 years, representing 17 cancer types, tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent (44 of 55 patients). At a median follow-up of 9.4 months, 86 percent of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. No patients discontinued treatment due to adverse side-effects.
“This study also demonstrates the shift from defining cancers by the site at which they occur toward defining them by the molecular changes that drive their growth,” Doebele says. “In terms of treatment, these trials show that rather than seeing these as ‘lung’ or ‘colorectal’ or other site-specific cancers, we can think of these as ‘TRK-fusion cancers’ and treat them according to this driver.”
Larotrectinib is one in a class of drugs known as tyrosine kinase inhibitors (TKIs), that block the action of target genes. Previously approved TKIs including crizotinib and alectinib inhibit the action of oncogenic genes ALK and ROS1. Larotrectinib uses a similar strategy to inhibit the gene TRK, which is active during early embryonic development, should remain silent in adult cells, but can be improperly reactivated by fusion with partner genes. Doebele and colleagues originally received the drug for study from Array BioPharma of Boulder, CO, and have developed it in partnership with Loxo Oncology of Stamford, CT.
“I can’t tell you how gratifying it is to see our early lab work with genes and cells leading to a treatment that is literally saving patients’ lives,” Doebele says. “This is the dream of all scientists who choose to go into cancer research.”
Due to the durability of responses to larotrectinib, the current studies will continue to follow patients to determine how long the drug is expected to control TRK-fusion cancer. Future studies are planned. Reported by PRWeb 1 week ago.
AURORA, Colo. (PRWEB) February 22, 2018
In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD, and Dana-Farber Cancer Institute investigator Pasi A. Jänne, MD, PhD reported in Nature Medicine the presence of TRK gene fusions as oncogenic drivers in patient samples of non-small cell lung cancer. Now five years later, the New England Journal of Medicine has published results of three early studies of the drug larotrectinib (formerly LOXO-101) to treat advanced-stage cancer patients whose tumors harbor these TRK fusion genes.
“The story of this drug demonstrates a new paradigm in anti-cancer drug development. We have discovery and validation of a new oncogenic driver, creation of an assay to find which cancers harbor TRK fusions, drug design and preclinical testing, and now academia-industry partnership that produces very promising clinical results,” says Doebele, director of the CU Cancer Center Thoracic Oncology Research Initiative and co-author of the current study.
The three clinical trials looked for TRK fusion genes in patients whose cancers had progressed after standard-of-care treatment (a phase 1 study involving adults, a phase 1–2 study involving children, and a phase 2 study involving adolescents and adults). Overall, 55 patients ranging in age from 4 months to 76 years, representing 17 cancer types, tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent (44 of 55 patients). At a median follow-up of 9.4 months, 86 percent of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. No patients discontinued treatment due to adverse side-effects.
“This study also demonstrates the shift from defining cancers by the site at which they occur toward defining them by the molecular changes that drive their growth,” Doebele says. “In terms of treatment, these trials show that rather than seeing these as ‘lung’ or ‘colorectal’ or other site-specific cancers, we can think of these as ‘TRK-fusion cancers’ and treat them according to this driver.”
Larotrectinib is one in a class of drugs known as tyrosine kinase inhibitors (TKIs), that block the action of target genes. Previously approved TKIs including crizotinib and alectinib inhibit the action of oncogenic genes ALK and ROS1. Larotrectinib uses a similar strategy to inhibit the gene TRK, which is active during early embryonic development, should remain silent in adult cells, but can be improperly reactivated by fusion with partner genes. Doebele and colleagues originally received the drug for study from Array BioPharma of Boulder, CO, and have developed it in partnership with Loxo Oncology of Stamford, CT.
“I can’t tell you how gratifying it is to see our early lab work with genes and cells leading to a treatment that is literally saving patients’ lives,” Doebele says. “This is the dream of all scientists who choose to go into cancer research.”
Due to the durability of responses to larotrectinib, the current studies will continue to follow patients to determine how long the drug is expected to control TRK-fusion cancer. Future studies are planned. Reported by PRWeb 1 week ago.
↧
PHOTOS: Children’s Hospital patients head to Rockies spring training camp
For the sixth year in a row, 27 patients of Children’s Hospital Colorado’s Center for Cancer and Blood Disorders set out on a trip to the Rockies spring training camp in Scottsdale, Arizona from the hospital in Aurora on Friday morning, March 2, 2018.
Reported by Denver Post 18 hours ago.
↧
Better Marijuana Stock: Aurora Cannabis vs. The Scotts Miracle-Gro Company
Which stock wins in a head-to-head match-up between a top marijuana grower and a leading marijuana supplies provider?
Reported by Motley Fool 5 hours ago.
↧
Officers’ suit for release of records to felon can continue
CHICAGO (AP) — A federal judge has given the green light to a lawsuit by seven police officers against the Chicago suburb of Aurora after an official sent their addresses, phone numbers and other personnel records to a purported street-gang leader they helped imprison to serve an 88-year sentence. The Chicago Daily Law Bulletin reports […]
Reported by Seattle Times 22 hours ago.
↧
↧
Take3: Husband and wife create award-winning cider in Aurora (Video)
Jonathan Rose visits a new cidery in Aurora. Created by a husband and wife team, their award-winning elixir takes off. Talia and Daniel Haykin are a husband-and-wife team that turned their passion into a business. As hobbyists they won national contests with their craft-made ciders, and now they're bringing their award-winning flavors to the Denver metro area with a brick-and-mortar shop.
Reported by bizjournals 7 hours ago.
↧
Nubian Resources bolsters senior management as it progresses towards Esquilache project acquisition
Nubian Resources Ltd (CVE:NBR) has unveiled some senior management changes as it continues towards its acquisition of the Esquilache silver-lead-zinc project in Peru, it told investors. William Brown has been hired as general manager of South America and Ashley Martin as business developer, the firm said. READ: Nubian Resources finalises due diligence on Esquilache project acquisition from Zinc One Resources Brown has over 30 years' experience in the junior exploration mining industry. Since 1993, he has been based in Latin America, principally Peru, Argentina, Brazil and Colombia, as well as several other countries. He boasts the outcrop discovery of the El Hilorico gold prospect in Peru on his CV, as well as the negotiation of the acquisition of Newmont Argentina SA for Aquiline Resources which included both the Calcatreu and Navidad projects. Meanwhile, Martin has over 12 years' mining construction and development experience. He was formerly with Guyana Goldfields, where he held a number of positions including manager, technical services, civil works manager and construction manager for the construction and commission of the Aurora gold mine. "We are very pleased to have Mr. Brown and Ms. Martin join the Nubian team. Technical report to be filed this month "Their extensive experience will be key for Nubian in Peru as the company progresses towards its acquisition of the Esquilache silver-lead-zinc project where CSA Global Pty Ltd. has completed their site visit. "We anticipate the National Instrument 43-101 technical report to be filed this month." As announced in September last year, the firm inked a binding letter of intent (LOI) with Zinc One Resources Inc to acquire the historic underground silver mine and adjacent Virgen de Chapi prospect. "Owning the Esquilache Project in Southern Peru will give Nubian immediate exposure to a near term development opportunity," Martin Walter, Nubian's chief executive, had said. "The Esquilache project contains silver lead and zinc mineralisation and a number of drill ready targets. "Our initial work programs will focus on working towards an initial resource calculation along with updating various past metallurgical and engineering studies."
Reported by Proactive Investors 6 hours ago.
↧
Home of the Day: Stunning Toll Brothers home in Cherry Creek schools!
By Sandy Kruse, Broker Associate Home of the Day is presented by the Denver Business Journal with Kentwood Real Estate. This is your invitation to view some of Denver's most-luxurious properties. Come inside and take a look around. Click on the gallery image to view today's featured property. Beacon Point26861 East Arbor Drive, Aurora, CO 80016 | $699,000 Beautiful Toll Brothers home in the heart of Beacon Point. This home featuring gleaming hardwood floors, dual staircases, soaring ceilings with…
Reported by bizjournals 5 hours ago.
↧
Road outside Smallfield school likely to be closed overnight due to burst water main
Sutton and East Surrey Water are conducting the repairs outside Aurora School
Reported by Surrey Mirror 4 hours ago.
↧
↧
10 Things You Should Know About Aurora Cannabis
Here's everything you need to know about the second-largest pot stock by market cap.
Reported by Motley Fool 2 hours ago.
↧
Aurora Public Schools to receive new turf field thanks to Denver Broncos grant
Aurora Public Schools will soon be the new owner of a synthetic turf field at Aurora Central High. The Denver Broncos and National Football League Foundation Grassroots Program will provide a $250,000 grant to install the new field, which is expected to be completed and unveiled this fall.
Reported by Denver Post 19 hours ago.
↧
TV Powerhouse Rachel Bloom Joins BE Conference at SXSW 2018!
Rachel Bloom, the co-creator and star of television hit comedy “Crazy Ex-Girlfriend,” will join TheWrap’s BE Conference for mentorship in a special one-on-one spotlight interview at SXSW on March 12.The second annual BE Conference for millennial women takes place on March 11 & 12 during SXSW.
Also newly added to the BE Conference lineup is the talented duo, writer-director Julia Hart and producer Jordan Horowitz (“La La Land”), with their film “Fast Color” which is premiering at SXSW.
They join a stunning lineup of inspiring women and mentors at TheWrap’s conference, including:
· Award-winning journalist Katie Couric
· Aurora Browne, Jennifer Whalen, and Meredith MacNeill of the Baroness von Sketch troupe;
· New York City Public Advocate Letitia James;
· Activists and Harvey Weinstein accusers Sarah Ann Masse and Jessica Barth;
· Pussyhat movement cofounder Jayna Zweiman and many others.
Check the full list of mentors and speakers at www.beconferences.com.
*Also Read:* Katie Couric, Baroness von Sketch Comedians to Headline Power Women, BE Conference at SXSW 2018!
Rachel Bloom is a rare multi-talented star, a performer, writer, director and improv and musical comedienne. She recently wrapped her third season starring in the CW show “Crazy Ex-Girlfriend,” for which she has won a Golden Globe and has been thrice nominated for the Emmy. The series stars Bloom as Rebecca Bunch, a successful, driven, and arguably crazy young woman who impulsively gives up everything – partnership at a prestigious law firm, an upscale apartment in Manhattan – in a desperate attempt to find love and happiness in suburban West Covina, California.
Bloom’s film “Most Likely to Murder,” written by Dan Gregor (her husband) and Doug Man, will premiere at SXSW. She costars in the dark comedy about a cool kid returning to his hometown 15 years after high school graduation.
Julia Hart is an up and coming female filmmaker with a passion for women’s issues. Hart directed “Fast Color,” which stars Gugu Mbatha-Raw, Lorraine Toussaint & David Strathairn. The film is produced and co-written by Jordan Horowitz.
Horowitz is an Academy Award nominated producer who most recently produced “La La Land.” At the 2017 Academy Awards, Horowitz entered the history books when he handed the Best Picture Oscar to Barry Jenkins after his film was mistakenly called as the winner. “La La Land” was nominated for a record 14 Oscars and won 6, including Best Director for Damien Chazelle and Best Actress for Emma Stone. Hart & Horowitz, partners in marriage and business co-founded the film and television production company Original Headquarters.
*Also Read:* Letitia James, Shelley Zalis, Sarah Ann Masse Join BE Conference 2018 as Speakers, Mentors
The BE Conference is a premier conference that connects change makers seeking to make an impact with game changers at the top of their fields who want to inspire and mentor the next generation of leaders. The audience consists of 350 millennials, including entrepreneurs, influencers and rising stars in their respective worlds, along with 50 mentors who are eager to teach and learn from each other.
Launched in 2017 by TheWrap founder and CEO Sharon Waxman, BE Conference offers keynote interviews, panel discussions, workshops, networking and mentoring sessions that build meaningful connections, encourage constructive change, and empower the next generation to BE the best possible version of themselves.
VIP tickets can be purchased for BE Conference 2018 and include exclusive access to mentors and entrance to Power Women Breakfast SXSW in Austin. More information on attending, sponsoring or mentoring at BE is available at Beconferences.com. Reported by The Wrap 19 hours ago.
↧
More Pages to Explore .....
